Shares of Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) fell 3.7% during trading on Friday. The company traded as low as $3.85 and last traded at $3.85. 200 shares traded hands during trading, a decline of 88% from the average daily volume of 1,720 shares. The stock had previously closed at $4.00.
Silence Therapeutics Price Performance
The stock’s 50-day moving average is $4.05 and its two-hundred day moving average is $2.58.
Silence Therapeutics Company Profile
Silence Therapeutics plc is a biotechnology company focused on developing medicines that use RNA interference (RNAi) to selectively reduce the production of disease-causing proteins. Its approach is designed to target specific messenger RNA molecules before they are translated into proteins, potentially enabling treatments for conditions that are difficult to address with conventional therapies.
The company’s proprietary mRNAi GOLD platform supports the design and delivery of small interfering RNA (siRNA) medicines, including compounds intended to target tissues outside the liver.
Further Reading
- Five stocks we like better than Silence Therapeutics
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
